一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Certolizumab

Certolizumab Struktur
428863-50-7
CAS-Nr.
428863-50-7
Englisch Name:
Certolizumab
Synonyma:
CERTOLIZUMAB PEGOL;Cimzia;Cdp870;Pha 738144;Unii-umd07X179e;Research Grade Certolizumab;Research Grade Certolizumab(DHB94401);(2S)-1-((2S)-6-aMino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid;Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated
CBNumber:
CB52497315
Summenformel:
C24H22F3N
Molgewicht:
381.4333896
MOL-Datei:
428863-50-7.mol

Certolizumab Eigenschaften

storage temp. 
Store at -20°C
Aggregatzustand
Liquid
Farbe
Colorless to light yellow

Sicherheit

Giftige Stoffe Daten 428863-50-7(Hazardous Substances Data)

Certolizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Certolizumab pegol, a tumor necrosis factor α(TNF-α) blocker, was launched for the treatment of moderate-to-severe Crohn’s disease. It is specifically indicated for reducing signs and symptoms and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy. Certolizumab pegol is the third anti-TNF-α biologic to be marketed for this indication behind infliximab (Remicade) and adalimumab (Humira). Certolizumab pegol is a recombinant, humanized antibody Fab’ fragment linked to approximately 40 kDa polyethylene glycol (PEG). The Fab’ fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 amino acids. It is manufactured in E.coli and is subsequently subjected to purification and conjugation to PEG, to generate certolizumab pegol. The addition of PEG moiety significantly enhances the plasma half-life of the antibody, allowing for less frequent dosing. Certolizumab pegol neutralizes both soluble and membrane-associated forms of human TNF-a. It binds to human TNF-a with slightly higher affinity (KD 0.09 nM) than infliximab (KD 0.23 nM) and adalimumab (KD 0.16 nM). In addition, in cellular assays, certolizumab pegol is more potent in preventing TNF-a-induced killing of L929 fibroblasts than infliximab and adalimumab (IC50 0.35 ng/mL versus 5 and 6 ng/mL, 592 Shridhar Hegde and Michelle Schmidt respectively).

Verwenden

Treatment of rheumatoid arthritis and inflammatory bowel disease.

Nebenwirkungen

The most common adverse reactions with certolizumab were upper respiratory infections (20%), urinary tract infections (7%), and anthralgias (6%). TNF-a blockers as a class have been linked to increased risk of opportunistic infections and malignancy. Tuberculosis, invasive fungal infections, and other serious infections have occurred in patients receiving certolizumab pegol, and the drug label contains a black-box warning of the risk.

Certolizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Certolizumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 18)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc.
+1-781-999-5354; +17819995354
marketing@targetmol.com United States 32466 58
BOC Sciences
16314854226; +16314854226
inquiry@bocsci.com United States 19853 58
Aladdin Scientific

tp@aladdinsci.com United States 52923 58
shanghai cooperpharm co.,LTD . +86-021-58975553
sales@cooperpharm.com China 1210 56
Shanghai Han-Xiang Chemical Co., Ltd. 15971444841 17754423994
candy@biochempartner.com China 3061 58
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10308 58
TargetMol Chemicals Inc. 4008200310 15002144251
marketing@tsbiochem.com China 24957 58
Biolab Reagents 027-65279366 18108604356
products@biolabreagent.com China 9865 58
Shanghai Yifei Biotechnology Co. , Ltd. 021-65675885 18964387627
customer_service@efebio.com China 11972 58
Wuhan Acumen Bio-Technology Co.,ltd 027-027-16602739303 16602739303
673003916@qq.com China 4590 58

  • Cdp870
  • Cimzia
  • Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated
  • Pha 738144
  • Unii-umd07X179e
  • (2S)-1-((2S)-6-aMino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid
  • Research Grade Certolizumab(DHB94401)
  • Research Grade Certolizumab
  • CERTOLIZUMAB PEGOL
  • 428863-50-7
Copyright 2019 ? ChemicalBook. All rights reserved
安阳县| 桐梓县| 孟津县| 乃东县| 新密市| 武宁县| 塘沽区| 北宁市| 九台市| 天峨县| 南溪县| 新密市| 离岛区| 丰县| 赤峰市| 永丰县| 青川县| 汉沽区| 江油市| 山西省| 玛纳斯县| 尖扎县| 乌海市| 宜兴市| 沙湾县| 紫金县| 平原县| 镇原县| 泰来县| 永春县| 诏安县| 鲁山县| 兴国县| 新余市| 安阳县| 印江| 黔西| 洪江市| 平定县| 河北省| 县级市|